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Abstract: 
Objectives: In this particular research we aimed to assess the correlation of hyperuricemia with gender and 
hypertension duration among selected patients.  
Material and Methods: We completed this cross-sectional research at Medicine Department of Mayo Hospital, 
Lahore in the timeframe of January 2017 to October 2017 on a total of 359 patients. The research sample consisted 
of 359 hypertension patients. We evaluated the relation of gender and hypertension with hyperuricemia among all the 
patients in ten months duration.  
Results: Selected patients were in the age bracket of (30 – 70) years with an average age of (50.91 ± 12.23). A total 
of 150 out of 359 hypertension patients (41.78%) were reported for Hyperuricemia. In terms of gender distribution, a 
total of 154 hypertensive patients (42.95%) were male and 205 hypertensive patients (57.10%) were female. Female 
population dominated the male population. Conclusion: The research outcomes clearly reflect an increased 
hyperuricemia rate among female population in comparison to the male hypertensive patients. We also report a 
significant statistical relation between hypertension duration and hyperuricemia among all the hypertensive patients. 
Keywords: Hypertension, Hyperuricemia, Stone, Urinary Tract, Hypertensive and DM (Diabetes Mellitus).  
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INTRODUCTION: 
There is no biochemical role of uric acid and it is an 
end product of purine metabolic system. Its initial 
discovery was made back in 1776 [1]. It was initially 
isolated from the stones of the urinary tract by Scheele 
(Swedish Chemist) back in 1776 [2]. Hypouricemia is 
a common issue of hypertensive male and female 
patients. The presence of hyperuricemia has a close 
link with hypertension initiation among patients [3]. 
Moreover, hypertension also increases the 
hyperuricemia frequency among patients.  
In the recent research studies, the fact of 
hyperuricemia involvement in cardiovascular disease 
is also under discussion [4]. Therefore, it is critical to 
control hyperuricemia for hypertension treatment. 
Hypertension and chronic heart failure require 
diuretics as management therapy which reportedly 
induces an onset of hyperuricemia. Therefore, 
combinational and safer management of diuretics 
possibly helps in the prevention of treatment 
associated onset of hyperuricemia. Hypertension 
management, especially among the patients with 
hyperuricemia, needs proper drug and dose selection 
that does not affect, reduce or influence uric acid 
concentration one way or the other [4]. Therefore, we 
aimed to assess the correlation of hyperuricemia with 
gender and hypertension duration among selected 
patients.  
 
MATERIAL AND METHODS: 
We completed this cross-sectional research at 
Medicine Department of Mayo Hospital, Lahore in the 
timeframe of January 2017 to October 2017 on a total 
of 359 patients. The research sample consisted of 359 
hypertension patients. We evaluated the relation of 
gender and hypertension with hyperuricemia among 
all the patients in ten months duration. Selected 
patients were in the age bracket of (30 – 70) years with 
an average age of (50.91 ± 12.23). We did not include 
any patient of gout, extra-articular hyperuricemia 
features, secondary hypertension, renal disease, intake 
of thiazide and loop diuretics. Institutional permission 
and patient’s informed consent was also taken before 
the research commencement.  
Every patient gave blood fasting sample (5 ml) for 
clinical investigation of uric acid. The analysis was 
made on an automated chemical analyzer and the 
measurement unit was (mg/dl). A value of (≥ 7.0) 
mg/dL fasting blood uric acid was taken as 
hyperuricemia. Every detail was documented about 
the demographic profile of the patients on a Performa. 
The researcher made a statistical analysis on SPSS 
software. Hypertension duration and age were 
quantitative variables which were measured in (Mean 
± SD). Hyperuricemia frequency and gender were 
qualitative variables and these variables were 
measured in number and percentage. Hyperuricemia 
was measured with the help of Pie chart. We also 
carried out stratification for hypertension duration, 
gender and age in order to compare their effect for 
various other variables. Lastly, we also made post 
stratification through the Chi-Square Test with a 
significant PValue of (≤ 0.05).  
 
RESULTS:  
Selected patients were in the age bracket of (30 – 70) 
years with an average age of (50.91 ± 12.23). A total 
of 150 out of 359 hypertension patients (41.78%) were 
reported for Hyperuricemia. In terms of gender 
distribution, a total of 154 hypertensive patients 
(42.95%) were male and 205 hypertensive patients 
(57.10%) were female. Female population dominated 
the male population. Among 359 patients the average 
hypertension duration was (18.84 ± 9.9) years. We 
generally made age stratification for (30 – 55) years 
and (56 – 70) years of age groups respectively 
including 219 and 96 140 patients with respective 
proportions of 61% and 39%. Hyperuricemia was 
reported in both groups respectively in 96 and 54 
patients having respective proportions of 43.84% and 
(38.57%). There was no significant link between 
hyperuricemia and age (P-Value = 0.380). Whereas, a 
higher significance was reported between 
hyperuricemia and gender (P-Value = 0.000). 
Minimum and maximum hypertension duration were 
respectively one year and forty-one years. 
Hypertension duration was also measured in two 
groups having (1 – 20) years and (21 – 41) years 
respective hypertension duration. A total of 50 patients 
were hypertensive (32.26%). In the hypertension 
duration bracket of (21 – 41) years 100 out of 204 
patients presented hyperuricemia (49%). There was a 
significant relationship between hyperuricemia and 
disease duration (P-Value = 0.002).  
Detailed outcomes analysis is available in the given 
tabular and graphical presentation (Table – I & II).  
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Table – I: Hyperuricemia Frequency 
 
Hyperuricemia  Number  Percentage  
Yes  150  58.22  
No  209  41.78  
  
  
 
  
Table – II: Gender, Age and Hypertension Duration Stratification 
  
Age, Gender and Hypertension 
Duration  
Yes  No  Total  
P-Value  
No  %  No  %  No  %  
Age  
30 – 55 Years   96  43.8  123  56.2  219  61.0  
0.380  56 – 70 Years  54  38.6  86  61.4  140  39.0  
Total   150  41.8  209  58.2  359  100.0  
Gender  
Male   45  29.2  109  70.8  154  42.9  
0.000  Female   105  51.2  100  48.8  205  57.1  
Total   150  41.8  209  58.2  359  100.0  
Hypertension 
Duration  
1 – 20 Years  50  32.3  105  67.7  155  43.2  
0.002  
21 – 41 Years  100  49.0  104  51.0  204  56.8  
 Total   150  41.8  209  58.2  359  100.0  
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DISCUSSION: 
Hyperuricemia has a strong relation with hypertension 
[5]. The uric acid possible pathogenic role and 
mechanism in hypertension is not fully understood but 
even then it includes endothelial nitric oxide reduction 
and also stimulates the expression of renin [6]. 
Hyperuricemia poses harmful effects on platelets 
adhesion and aggregation, endothelial function and 
oxidative metabolism as well [7]. It also exercises 
hyperuricemia inducing mechanisms. It is capable to 
reduce the renal blood flow rate which stimulates 
microvascular/capillary tissue ischemia and urate 
reabsorption. Microvascular/capillary tissue ischemia 
may cause increased lactates production that blocks or 
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inhibits secretion of urate in proximal tubes, increased 
the xanthine oxidase production and purine 
breakdown which leads to increased production of 
urate and the enhanced onset of hyperuricemia [8].  
We calculated an average age and average 
hypertension duration respectively as (50.91 ± 12.23) 
years and (18.84 ± 9.9) years which same as reported 
in a research conducted by a local author Ahmed and 
his colleagues [9]. We reported that females were 
more involved in the incidence of hyperuricemia than 
males. In the total hypertensive patients, the 
hyperuricemia patients were about 41.78%. Ahmed 
reported 37.4% of hypertensive patients presenting 
hyperuricemia; moreover, these outcomes are also 
similar to our reported outcomes [9]. Schmidt also 
reported the common frequency of hyperuricemia in 
patients who presented hypertension (20.1%) in 
comparison to the patients who did not present any 
sign of hypertension (6.7%) in series [10]. The 
outcomes presented by Schmidt are not concurrent 
with the outcomes of this particular research study. 
Afifi also reported 55.4% frequency of hyperuricemia 
among hypertensive patients [11]. Rahman reported 
40.3% frequency of hyperuricemia among 
hypertensive patients [12]. Our research outcomes are 
in agreement with the outcomes presented by Afifi and 
Rahman [11, 12].  
According to the research outcomes of Poudel the 
prevalence of hyperuricemia was 28.8% among 
hypertensive patients; whereas, in the research 
outcomes of Kashem and Sachdev the prevalence of 
hyperuricemia was respectively 25.4% and 13.5% 
among hypertensive patients [13 – 15]. The outcomes 
presented by Poudel, Kashem and Sachdev are not in 
agreement with the research outcomes presented in our 
series [13 – 15]. Afifi presented no significant 
association of hyperuricemia to age; whereas we 
reported a significant link between both variables with 
a significant P-Value of (< 0.05) [11].  
 
CONCLUSION: 
Both early and older age groups of females are more 
involved in hyperuricemia. Moreover, hypertension 
duration is significantly correlated with the increased 
level of uric acid. The research outcomes clearly 
reflect an increased hyperuricemia rate among female 
population in comparison to the male hypertensive 
patients. We also report a significant statistical relation 
between hypertension duration and hyperuricemia 
among all the hypertensive patients.  
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